KEY DETAILS
Brazil's regulator Anvisa approved five semaglutide pens modeled on Ozempic for adults with type 2 diabetes, after Novo Nordisk's semaglutide patent expired there in March.
Novo Nordisk lost about $30 billion in market value after its heart drug ziltivekimab, which is not a GLP-1, did not reduce major heart events in the Phase 3 ZEUS trial.
The VA launched a trial testing weekly semaglutide against a placebo in more than 600 veterans with alcohol use disorder at 18 VA medical centers.
A clinical trial found oral semaglutide may help curb heavy drinking in adults.
A BMJ study of adults with type 2 diabetes linked GLP-1 use to a higher rate of usually temporary hair loss than two other diabetes drug classes, though the risk was low.
Brazil's health regulator has approved five semaglutide pens, registered by comparison to Ozempic, for adults with type 2 diabetes, a sign of how quickly this market is expanding now that Novo Nordisk's semaglutide patent has expired there. The same week brought a sharp financial setback for Novo Nordisk and new research pointing to both risks and possible new uses for these medications. Together, the updates show how fast this treatment category is moving on several fronts at once, and why it may be worth paying attention if you or a family member uses one of these drugs.
Anvisa's approval of the five semaglutide pens, named Owozy, Seemasun, Zempneo, Semavy and Orsema, came after Novo Nordisk's semaglutide patent expired in Brazil in March, which opened the door to a wave of expedited regulatory reviews. This kind of patent expiration tends to invite more manufacturers into a market, which can eventually widen access and lower prices. For now, these pens are approved for adults with type 2 diabetes, not for weight loss. Readers outside Brazil should watch whether similar patent timelines in their own countries lead to comparable regulatory movement, since that pattern often signals more competition ahead.
Novo Nordisk lost about $30 billion in market value after its experimental heart drug ziltivekimab, which is not a GLP-1, did not reduce heart attacks, strokes and other major heart events in the Phase 3 ZEUS trial, and analysts were critical of the result. A setback like this can affect how much a company invests in future research, which matters to patients who depend on a steady pipeline of new treatment options. It is a reminder that drug development carries real financial risk for manufacturers, even when a company already has a well established product on the market.
The Department of Veterans Affairs has launched a clinical trial testing weekly semaglutide against a placebo for 24 weeks in more than 600 veterans aged 18 to 80 with moderate or severe alcohol use disorder, at 18 VA medical centers. Diabetes is not required to take part. This trial reflects a broader interest in whether GLP-1 medications, originally developed for blood sugar control and weight loss, might also help with alcohol use disorder. For veterans enrolled in the study, the outcome could open a new treatment path, and the results may also inform how these drugs are studied in other populations with similar struggles.
A separate clinical trial found that oral semaglutide may help curb heavy drinking in adults with alcohol use disorder, with participants showing improvements compared to those on a placebo. This finding adds to the growing body of research exploring GLP-1 drugs beyond their original purpose. If you are considering a GLP-1 medication for reasons outside diabetes or obesity, it would be wise to talk with your doctor about what the current evidence does and does not support, since this research is still developing.
A BMJ study of adults with type 2 diabetes linked GLP-1 use to a higher risk of non-scarring alopecia, a type of hair loss that is usually temporary, compared with people taking two other classes of diabetes drugs, SGLT-2 and DPP-4 inhibitors. The absolute risk was low, about 6 or 7 in 1,000 people a year. This finding does not mean hair loss will happen to every user, but it does add another item to the list of side effects patients may want to discuss with their prescriber. Anyone noticing unexpected hair thinning while on a GLP-1 medication should bring it up at their next appointment rather than assuming it is unrelated.
These five stories, taken together, show a treatment category that is expanding in availability while also facing new questions about safety and effectiveness beyond its original use. If you are currently taking a GLP-1 medication or considering one, I would suggest keeping an open conversation with your doctor about both the benefits you are seeking and any side effects you notice along the way. The research on alcohol use disorder and hair loss is still early, so it is reasonable to stay informed without changing your treatment plan based on a single study. As always, the right next step depends on your own health history and goals, and that conversation is best had directly with your care provider.
Sources
Novo Nordisk’s Market Value Sheds $30 Billion-Here’s Why Shares Are Down — Forbes
VA announces launch of GLP-1 treatment to help veterans struggling with alcohol — Baltimore News
VA announces launch of GLP-1 treatment to help veterans struggling with alcohol — WJLA
Ozempic is giving people ‘temporal hollowing.’ What is it? — USA TODAY
Cigna Expects Lower Growth in Popular GLP-1 Drug Prescriptions — Benzinga
Indiana Medicaid to opt into discounted obesity drug program — South Bend Tribune
Eli Lilly taps Ohio manufacturer to boost GLP-1 production — Cincinnati Cincinnati Enquirer
1 drugs like Ozempic increase hair loss risk? — Medical News Today